July 2011
ActiveSite awarded United States Patent 7,977,380, Inhibitors of Plasma Kallikrein.
March 2011
ActiveSite Pharmaceuticals' Small Molecule Protease Inhibitor
Blocks Retinal Blood Vessel Damage in Rodent Model of Diabetes,
Press Release, ActiveSite Pharmaceuticals.
Plasma Kallikrein Mediates Retinal Vascular Dysfunction and Induces
Retinal Thickening in Diabetic Rats, Diabetes, online publication Mar 28 (2011).
February 2011
Hyperglycemia-induced Cerebral Hematoma Expansion is Mediated by Plasma
Kallikrein, Nature Medicine, 17, pp 206-10 (2011).
November 2010
ActiveSite awarded Qualifying Therapeutic Discovery Project Grant for
Preclinical & Early Clinical Development of a NCE Targeting Diabetic Macular Edema.
December 2009
ActiveSite awarded United States Patent 7,625,944, Inhibitors of Plasma Kallikrein.
July 2009
ActiveSite awarded SBIR Phase II Grant from the National Eye Institute, Novel
Orally-active Plasma Kallikrein Inhibitors for Diabetic Retinopathy.
January 2009
Researchers Describe Protease Inhibitor That May Aid in Diabetic
Retinopathy Treatment, Press Release, Juvenile Diabetes Research Foundation.
Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated
retinal vascular permeability, Hypertension, 53, pp 175-81 (2009).
September 2007
ActiveSite awarded SBIR Phase I Grant from the National Heart Lung and
Blood Institute, Novel Anti-thrombotic Approach for Treatment of Myocardial Infarction.
|